Compare · ARDX vs TCDA
ARDX vs TCDA
Side-by-side comparison of Ardelyx Inc. (ARDX) and Tricida Inc. (TCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARDX and TCDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARDX is the larger of the two at $1.28B, about 2.3x TCDA ($550.1M).
- ARDX has hit the wire 2 times in the past 4 weeks while TCDA has been quiet.
- ARDX has more recent analyst coverage (24 ratings vs 2 for TCDA).
- Company
- Ardelyx Inc.
- Tricida Inc.
- Price
- $5.20+1.36%
- $0.10-19.25%
- Market cap
- $1.28B
- $550.1M
- 1M return
- -8.29%
- -
- 1Y return
- +17.78%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 2
- 0
- Recent ratings
- 24
- 2
Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Tricida Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest ARDX
- President & CEO Raab Michael exercised 20,834 shares at a strike of $0.99 and sold $210,923 worth of shares (41,668 units at $5.06) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,678,366 units (SEC Form 4)
- Ardelyx Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Patient Officer Williams Laura A exercised 31,000 shares at a strike of $0.99 and sold $490,487 worth of shares (81,898 units at $5.99) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 378,195 units (SEC Form 4)
- Director Parsey Merdad was granted 26,455 shares, increasing direct ownership by 46% to 83,746 units (SEC Form 4)
- Director Rodgers Richard J was granted 26,455 shares, increasing direct ownership by 6% to 439,998 units (SEC Form 4)
- Director Mott David M was granted 46,737 shares, increasing direct ownership by 1% to 3,349,655 units (SEC Form 4)
- Director Cadoret-Manier Onaiza was granted 26,455 shares, increasing direct ownership by 17% to 178,156 units (SEC Form 4)
- Director Bhanji Muna was granted 26,455 shares, increasing direct ownership by 19% to 163,808 units (SEC Form 4)
- Director Bertrand William C Jr was granted 38,800 shares, increasing direct ownership by 13% to 329,507 units (SEC Form 4)
- Director Bazemore Robert B was granted 26,455 shares, increasing direct ownership by 64% to 68,006 units (SEC Form 4)
Latest TCDA
- SEC Form EFFECT filed by Tricida Inc.
- SEC Form 15-12G filed by Tricida Inc.
- SEC Form S-8 POS filed by Tricida Inc.
- SEC Form POSASR filed by Tricida Inc.
- SEC Form POS AM filed by Tricida Inc.
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits